A Phase I/II Study of Ado-Trastuzumab Emtansine (T-DM1) + ABT-737 in Treating Patients With HER2(+) Breast Cancer

Trial Profile

A Phase I/II Study of Ado-Trastuzumab Emtansine (T-DM1) + ABT-737 in Treating Patients With HER2(+) Breast Cancer

Withdrawn prior to enrolment
Phase of Trial: Phase I/II

Latest Information Update: 17 Jun 2014

At a glance

  • Drugs ABT 737 (Primary) ; Trastuzumab emtansine
  • Indications Breast cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 30 May 2014 According to the ClinicalTrials.gov record, status changed from recruiting to withdrawn prior to recruitment.
    • 19 Mar 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top